Ultra sensitive (1.279 pg/ml) ELISA kit, enabling reduced input sample and matrix interference, for the quantification of KIM-1, an early biomarker for kidney injury or disease.
Sensitive – reliably measure as little as 1.279 pg/ml of KIM-1
High Throughput – results in <2 hours from up to 38 samples in duplicate
Specific – low cross-reactivity to similar proteins
Quantitative – fully quantitative results for both normal and disease state samples that surpass semi-quantitative Western blot analysis
The KIM-1 (human) ELISA kit is a complete, colorimetric, immunometric immunoassay kit for the quantitative determination of human KIM-1 in urine with results in <2 hours.
Please mouse over
Product Details
Alternative Name:
Kidney injury molecule-1, T-cell immunoglobulin and mucin domain-containing protein 1, TIMD-1, TIM-1, HAVCR1, Hepatitis A virus cellular receptor 1, T-cell immunoglobulin mucin receptor 1, CD365
Sensitivity:
1.279 pg/ml (range 7.813 - 500 pg/ml)
Assay Time:
<2 hours
Applications:
ELISA, Colorimetric detection
Application Notes:
For the quantitative determination of human KIM-1 in urine.
Wavelength:
450 nm
Species reactivity:
Human
Crossreactivity:
No cross reactivity to similar molecules (< 0.02% TIM-3, TIM-4).
Chronic kidney disease (CKD) is a major public health problem, as one in nine American adults have CKD. There have been numerous studies focused on this disease over the years but there remains a need for improved therapeutics and identifying and/or predicting patient outcomes. One protein that has been identified as playing an important role in kidney disease is Kidney Injury Molecule-1 (KIM-1). KIM-1 is a 30KDa, type 1 membrane protein with an ectodomain that contains immunoglobulin and highly O-glycosylated mucin subdomains as well as multiple N-glycosylation sites. It is the most highly upregulated protein in the proximal tubule of the injured kidney. It exists in very low levels in normal kidneys but when upregulated during injury, it is detectable in urine in a wide variety of human diseases. KIM-1 is a potential biomarker for renal injury, which would suggest it has great importance in various kidney diseases and disorders, such as chronic kidney disease (as mentioned above), as well as acute tubular necrosis and acute kidney failure.
Technical Info/Product Notes:
This product is licensed from the General Hospital Corporation and is protected by US patents 6,664,385 B1, 7,041,290 B2 and 7,696,321.
Identification of Pre-Renal and Intrinsic Acute Kidney Injury by Anamnestic and Biochemical Criteria: Distinct Association with Urinary Injury Biomarke: S.M. Sancho-Martínez, et al.; Int. J. Mol. Sci. 24, 1826 (2023), Abstract;
Early Diagnosis of Kidney Damage Associated with Tobacco Use: Preventive Application: J. Tascón, et al.; J. Pers. Med. 12, 1032 (2022), Abstract;
The effect of interval and continuous work on markers of acute kidney injury in a hot environment: J. Houck, et al.; Eur. J. Appl. Physiol. 122, 2437 (2022), Abstract;
Adverse Health Effects in Women Farmers Indirectly Exposed to Pesticides: J. Martin-Reina, et al.; Int. J. Environ. Res. Public Health 18, 5909 (2021), Application(s): Human urine, Abstract; Full Text
The Effects of Beverage Intake after Exhaustive Exercise on Organ Damage, Inflammation and Oxidative Stress in Healthy Males: T. Tominaga, et al.; Antioxidants (Basel) 10, 866 (2021), Application(s): KIM-1 quantification on human urine and plasma samples, Abstract; Full Text
Biomarkers in the prediction of contrast media induced nephropathy – the BITCOIN study: F.S. Seibert, et al.; PLoS One 15, e0234921 (2020), Abstract; Full Text
Designing new diagnostic systems for the early detection of tobacco-associated chronic renal damage in patients of a primary care centre in Salamanca, Spain: an observational, prospective study protocol: M. Prieto, et al.; BMJ Open 10, e032918 (2020), Abstract; Full Text
Quercetin, a promising clinical candidate for the prevention of contrast-induced nephropathy: L. Vicente-Vicente, et al.; Int. J. Mol. Sci. 20, 4961 (2019), Application(s): ELISA using human urine, Abstract; Full Text
Prognostic Value of Urinary Calprotectin, NGAL and KIM-1 in Chronic Kidney Disease: F.S. Seibert, et al.; Kidney Blood Press Res. 43, 1255 (2018), Abstract; Full Text
Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy: J. Neuhaus, et al.; Kidney Blood Press Res. 43, 1563 (2018), Abstract; Full Text
Hepatic ischemia/reperfusion injury associates with acute kidney injury in liver transplantation: prospective cohort study: I. Jochmans, et al.; Liver Transpl. 23, 634 (2017), Application(s): ELISA using human urine, Abstract;
Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury: J.H. Westhoff, et al.; Eur. J. Pediatr. 176, 745 (2017), Application(s): ELISA using human urine, Abstract;
Acute kidney injury prediction in cardiac surgery patients by a urinary peptide pattern: a case-control validation study: J. Metzger, et al.; Crit. Care 20, 157 (2016), Application(s): ELISA using human urine, Abstract; Full Text
Urinary biomarkers for the differentiation of prerenal and intrinsic pediatric acute kidney injury: J.H. Westhoff, et al.; Pediatr. Nephrol. 31, 2353 (2016), Application(s): ELISA using human urine, Abstract;
Estimation of kidney injury molecule-1 (Kim-1) in patients with lupus nephritis: Y. Nozaki, et al.; Lupus 23, 769 (2014), Abstract;
NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction: L. Holzscheiter, et al.; Clin. Chem. Lab. Med. 52, 537 (2014), Abstract;
Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients: S.S. Kim, et al.; Diabetes Metab. Res. Rev. 30, 736 (2014), Abstract;
Renal neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 expression in children with acute kidney injury and Henoch-Schönlein purpura nephritis: Y. Du, et al.; Exp. Ther. Med. 7, 1130 (2014), Abstract; Full Text
Serum and urinary NGAL but not KIM-1 raises in human postrenal AKI: A. Urbschat, et al.; Eur. J. Clin. Invest. 44, 652 (2014), Abstract;
General Literature References
Application of emerging biomarkers of acute kidney injury in development of kidney-sparing polypeptide-based antibiotics: D. Burt, et al.; Drug Chem. Toxicol. 37, 204 (2014), Abstract;
